Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.
Investigators also investigate how genetic variants may affect cancer treatment, at various stages of disease development, in order to determine prognostic and predictive factors for survival.
Study Type
OBSERVATIONAL
Enrollment
15,000
Massachusetts General Hospital
Boston, Massachusetts, United States
RECRUITINGSurvival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression
Study lung cancer development in a case control study. We will look at three separate outcome measures specified below
Time frame: 20 years
Overall survival
Measurement from time of diagnosis to death will be obtained
Time frame: 20 years
Progression-free survival
Time of diagnosis to disease progression (measured by metastasis)
Time frame: 20 years
Treatment toxicities
Effects on ECOG and physical sequelae from treatment (radiation, chemotherapy and other treatment modalities will be analyzed)
Time frame: 20 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.